N. Uemura

ORCID: 0000-0003-2670-9299
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Particle physics theoretical and experimental studies
  • High-Energy Particle Collisions Research
  • Quantum Chromodynamics and Particle Interactions
  • Boron and Carbon Nanomaterials Research
  • Dark Matter and Cosmic Phenomena
  • Chronic Lymphocytic Leukemia Research
  • Glycosylation and Glycoproteins Research
  • Chronic Myeloid Leukemia Treatments
  • Particle Accelerators and Free-Electron Lasers
  • MXene and MAX Phase Materials
  • Gastric Cancer Management and Outcomes
  • Metastasis and carcinoma case studies
  • Multiple Myeloma Research and Treatments
  • Particle Detector Development and Performance
  • Galectins and Cancer Biology
  • Gastrointestinal Tumor Research and Treatment
  • Boron Compounds in Chemistry
  • Cancer Treatment and Pharmacology
  • RNA Interference and Gene Delivery
  • Advanced ceramic materials synthesis
  • Lymphoma Diagnosis and Treatment
  • Cancer Research and Treatments
  • Bone and Dental Protein Studies
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Magnesium Alloys: Properties and Applications

University of Electro-Communications
2025

Kyoto University of Advanced Science
2024

University of Tsukuba
1992-2022

Idemitsu Kosan (Japan)
2022

Kumamoto Medical Center
2020

Nagoya Institute of Technology
2019

Osaka University
2012-2017

Sapporo Medical University
2013-2017

Kyushu University
2016-2017

Muroran Institute of Technology
2016

The Philadelphia chromosome translocation generates a chimeric oncogene, BCR/ABL, which causes chronic myelogenous leukemia (CML). In primary neutrophils from patients with CML, the major novel tyrosine-phosphorylated protein is CRKL, an SH2-SH3-SH3 linker has overall homology of 60% to CRK, human homologue v-crk oncogene product. Anti-CRKL immunoprecipitates CML cells, but not normal were found contain p210BCR/ABL and c-ABL. Several other phosphoproteins also detected in anti-CRKL...

10.1074/jbc.270.49.29145 article EN cc-by Journal of Biological Chemistry 1995-12-01

Crkl, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in cells from patients with chronic myelogenous leukemia. Crkl binds to BCR/ABL through its N-terminal SH3 domain and known interact several signaling proteins that have been implicated integrin signaling, including Cbl, Cas, Hef-1, paxillin. We previously shown overexpression enhances adhesion extracellular matrix β<sub>1</sub> integrins. In this study, effects on spontaneous chemokine-directed...

10.1074/jbc.274.53.37525 article EN cc-by Journal of Biological Chemistry 1999-12-01

We have resolved long-standing discrepancies between the theoretical and experimental crystal structures of boron carbide ${\mathrm{B}}_{13}{\mathrm{C}}_{2}$. Theoretical studies predict that ${\mathrm{B}}_{13}{\mathrm{C}}_{2}$ should be stoichiometric highest symmetry carbides. Experimentally, is a semiconductor many defect states been reported, particularly in CBC chain. Reconciling disordered chain, chemical composition, lowest-energy state problematic. solved this problem by constructing...

10.1103/physrevb.90.064109 article EN Physical Review B 2014-08-26

CRKL is an SH2-SH3-SH3 adapter protein that a major substrate of the BCR/ABL oncogene. The function in normal cells unknown. In transformed by we have previously shown associated with two focal adhesion proteins, tensin and paxillin, suggesting could be involved integrin signaling. hematopoietic cell lines, MO7e H9, found rapidly associates tyrosine-phosphorylated proteins after cross-linking β1 integrins fibronectin or anti-β1 monoclonal antibodies. CRKL-binding megakaryocytic was...

10.1074/jbc.272.22.14320 article EN cc-by Journal of Biological Chemistry 1997-05-01

Background: Fucose is utilized for the modification of different molecules involved in blood group determination, immunological reactions, and signal transduction pathways. We have recently reported that enhanced activity fucosyltransferase 3 and/or 6 promoted TGF-ß-mediated epithelial mesenchymal transition was associated with increased metastatic potential colorectal cancer (CRC), suggesting fucose required by CRC cells. With this mind, we examined requirement L-fucose cells developed...

10.1093/jnci/djw210 article EN JNCI Journal of the National Cancer Institute 2016-09-01

Fucose is utilized for the modification of different molecules involved in blood group determination, immunological reactions, and signal transduction pathways. We have recently reported that enhanced activity fucosyltransferase 3 and/or 6 promoted TGF-ß-mediated epithelial mesenchymal transition was associated with increased metastatic potential colorectal cancer (CRC), suggesting fucose required by CRC cells. With this mind, we examined requirement L-fucose cells developed fucose-bound...

10.1093/jnci/djw038 article EN JNCI Journal of the National Cancer Institute 2016-04-13

Recent discoveries of supposedly pure alpha-tetragonal boron require to revisit its structure. The system is also interesting with respect a new type geometrical frustration in elemental crystals, which was found beta-rhombohedral boron. Based on density functional theory calculations, the present study has resolved structural and thermodynamic characteristics Different from boron, conditions for stable covalent bonding (a band gap completely filled valence bands) are almost fulfilled at...

10.1103/physrevb.93.104101 article EN Physical review. B./Physical review. B 2016-03-01

Abstract Background. Survivin is highly expressed in cancer cells but shows little or no expression normal tissues. Little known about antibody responses to survivin patients with head and neck cancer. Methods. Anti‐survivin were investigated by enzyme‐linked immunosorbent assay. Anti‐p53 squamous cell carcinoma antigen also examined. Results. Sera from 69 of 97 (71.1%) positive for anti‐survivin, a cutoff value (absorbance; &gt;0.673) healthy control subjects. High levels anti‐survivin...

10.1002/hed.20652 article EN Head & Neck 2007-07-16
Coming Soon ...